Pfizer Q2 2026 Earnings reveal a strong biopharmaceutical operational performance, with total quarterly revenues increasing 3% reported (1% operationally) to $15.034 billion compared to $14.653 billion in the second quarter of 2025. Driven by an 18% operational expansion across newly launched and acquired commercial products, top-line performance surpassed Wall Street consensus estimates of $14.40 billion. Non-GAAP Adjusted Diluted Earnings Per Share (EPS) reached $0.77, exceeding consensus projections of $0.68 per share while maintaining stability alongside prior-year results of $0.78.
On a GAAP reported basis, the company recorded a net loss of $(248) million, translating to a diluted loss per share (LPS) of $(0.04), compared to net income of $2.910 billion, or $0.51 per share, in Q2 2025. This reported loss was primarily driven by $4.3 billion in pre-tax non-cash intangible asset impairment charges following portfolio re-evaluations, a primary factor analyzed in the Pfizer Q2 2026 Earnings presentation. Non-GAAP Adjusted Net Income stood flat at $4.440 billion relative to $4.434 billion in the prior-year period, as growth across core oncology and specialty care platforms successfully absorbed elevated late-stage research investments.
The divergence between GAAP reported metrics and Non-GAAP measures extended to corporate tax dynamics during the quarter. Pfizer recorded a GAAP effective tax rate of 62.4% due to pre-tax loss benefits and foreign jurisdictional earnings mix, while its effective tax rate on Adjusted Income settled at 14.1%.
Non-COVID Biopharmaceuticals Drive Growth in Pfizer Q2 2026 Earnings
Excluding contributions from pandemic products Comirnaty and Paxlovid, Pfizer’s core commercial operations expanded 5% operationally year-over-year. The Vyndaqel family of treatments (Vyndaqel, Vyndamax, Vynmac) generated $1.762 billion globally for an 8% operational increase, driven by expanded diagnostic adoption and heightened international awareness for transthyretin amyloid cardiomyopathy (ATTR-CM). Eliquis achieved 19% global operational growth, propelled by favorable U.S. gross-to-net pricing dynamics and strong demand, as highlighted during the Pfizer Q2 2026 Earnings webcast.
Key oncology products registered significant double-digit operational expansion across global markets. Padcev delivered $667 million in sales (up 23% operationally) due to market share gains in first-line locally advanced or metastatic urothelial cancer (la/mUC) and launch uptake in muscle-invasive bladder cancer (MIBC). Lorbrena reached $354 million (up 37% operationally), Braftovi/Mektovi contributed $223 million (up 23% operationally), and Orgovyx surged 51% to $146 million.
Financial Guidance and Cost Realignment Highlights in Pfizer Q2 2026 Earnings
Because non-COVID commercial products delivered a $1.5 billion operational beat against internal projections in the first half of the year, Pfizer raised the midpoint of its full-year 2026 total revenue guidance by $500 million to a revised range of $60.5 billion to $62.5 billion. Full-year Adjusted Diluted EPS guidance was reaffirmed at $2.80 to $3.00, absorbing a ~$0.10 per share charge from business development transactions, as demonstrated in the updated projections within the Pfizer Q2 2026 Earnings report.
To safeguard operating margins ahead of late-decade loss-of-exclusivity events, Pfizer expanded its structural savings initiatives. The multi-year Realigning Our Cost Base Program was expanded to target ~$6.7 billion in cumulative net cost savings through 2029, incorporating an additional $1.0 billion net reduction target announced in Q2. Concurrently, Phase 2 of the COGS / Manufacturing Optimization Program was launched to deliver an additional $1.5 billion in net manufacturing savings, bringing cumulative manufacturing targets to $3.0 billion by 2029.
| Financial Metric | Q2 2026 Value | Q2 2025 Value | Operational Growth (%) | Full-Year 2026 Guidance |
| Total Revenues | $15,034M | $14,653M | 1% | $60.5B – $62.5B |
| GAAP Net Income (Loss) | $(248)M | $2,910M | N/A | N/A |
| GAAP Diluted EPS (LPS) | $(0.04) | $0.51 | N/A | N/A |
| Adjusted Net Income | $4,440M | $4,434M | 0% | N/A |
| Adjusted Diluted EPS | $0.77 | $0.78 | (1%) | $2.80 – $3.00 |
| Adjusted Cost of Sales (% Revenue) | 24.3% | 23.3% | N/A | N/A |
| Adjusted SI&A Expenses | $3,344M | $3,450M | (3%) | $12.5B – $13.5B |
| Adjusted R&D Expenses | $2,730M | $2,442M | 12% | $10.5B – $11.5B |
Pipeline Milestones and Strategic Transactions Shaping Pfizer Q2 2026 Earnings
On July 10, 2026, Pfizer finalized a licensing and co-development transaction with Innovent Biologics to advance 12 clinical-stage and de novo oncology candidates, focusing on novel antibody-drug conjugates (ADCs) and multi-specific antibodies. The deal featured a $650 million upfront payment that will be recorded as an Acquired In-Process R&D charge in Q3 2026, contributing significantly to the strategic outlook surrounding Pfizer Q2 2026 Earnings [cite: 1, 4]. Key regulatory approvals included FDA clearance for Padcev plus pembrolizumab in perioperative muscle-invasive bladder cancer, alongside FDA Priority Review for Talzenna plus Xtandi in mCSPC based on Phase 3 TALAPRO-3 trial data [cite: 4]. Furthermore, updated seven-year data from the Phase 3 CROWN study showed Lorbrena reduced progression or death risk by 81% ($\text{HR} = 0.19$) in ALK-positive NSCLC.
Capital deployment during the first half of 2026 totaled $5.3 billion invested in internal R&D and $4.9 billion returned to shareholders via common stock dividends ($0.86 per share). Share buybacks remained paused to prioritize balance sheet deleveraging. Corporate governance updates confirmed that CFO Dave Denton stepped down on August 15, 2026, with Cecile Guegan assuming the Interim CFO role on August 16, 2026, providing a stable management baseline beyond the Pfizer Q2 2026 Earnings cycle.
Granular Revenue Performance by Commercial Asset
Oncology Portfolio Sales Breakdown
- Ibrance: Generated $1,058 million globally (0% operational change; U.S. $707 million, up 2%; International $351 million, down 4% operationally due to price adjustments).
- Padcev: Generated $667 million globally (up 23% operationally; U.S. $648 million, up 21%; International $19 million).
- Xtandi: Generated $534 million globally (down 6% operationally, entirely U.S. revenue).
- Lorbrena: Generated $354 million globally (up 37% operationally; U.S. $133 million, up 33%; International $221 million, up 40% operationally on strong 1L ALK+ NSCLC adoption).
- Braftovi / Mektovi: Generated $223 million globally (up 23% operationally; U.S. $208 million, up 21%; International $16 million, up 48% operationally).
- Inlyta: Generated $218 million globally (down 12% operationally; U.S. $114 million; International $105 million).
- Adcetris: Generated $196 million globally (down 23% operationally; U.S. $192 million).
- Orgovyx: Generated $146 million globally (up 51% operationally, entirely U.S.).
- Tukysa: Generated $138 million globally (up 4% operationally; U.S. $96 million; International $42 million, up 67% operationally).
- Bosulif: Generated $113 million globally (down 24% operationally).
- Elrexfio: Generated $89 million globally (up 5% operationally; U.S. $30 million; International $59 million, up 18% operationally).
- Talzenna: Generated $57 million globally (up 23% operationally; U.S. $40 million; International $17 million).
- Tivdak: Generated $34 million globally (down 25% operationally).
Specialty Care, Hospital & Biosimilar Portfolio Sales
- Vyndaqel Family: Generated $1,762 million globally (up 8% operationally; U.S. $1,064 million, up 7%; International $698 million, up 8% operationally on diagnosis penetration).
- Oncology Biosimilars: Generated $359 million globally (up 1% operationally; U.S. $249 million; International $110 million).
- Xeljanz: Generated $251 million globally (down 23% operationally; U.S. $140 million, down 32%; International $111 million, down 6% operationally).
- Zavicefta: Generated $199 million globally (up 17% operationally, ex-U.S./Canada).
- Inflectra: Generated $171 million globally (up 23% operationally; U.S. $165 million, up 66%).
- Enbrel: Generated $142 million globally (down 10% operationally, ex-U.S./Canada).
- Octagam: Generated $138 million globally (up 43% operationally).
- Sulperazon: Generated $116 million globally (down 34% operationally, ex-U.S./Canada).
- Cresemba: Generated $106 million globally (down 10% operationally, ex-U.S./Canada).
- Genotropin: Generated $94 million globally (down 15% operationally).
- Cibinqo: Generated $94 million globally (up 34% operationally; U.S. $34 million, up 39%; International $61 million, up 32% operationally).
